Fig. 2. Frequency of new molecular entities (NMEs, i.e. new drug candiddates) in inhibition-based drug-drug interactions (DDIs) with drugs approved by the Food and Drug Administration (FDA) in the United States between 2013 and 2016 (
Yu et al., 2018). (A) Grouping by therapeutic class. (B) Grouping by enzymes involved. Pgp and OAT1B1 are transporters. COMT: catechol
O-methyl transferase.
